167 related articles for article (PubMed ID: 3487139)
1. Heterogeneity of factor IX BM. Difference of cleavage sites by factor XIa and Ca2+ in factor IX Kashihara, factor IX Nagoya and factor IX Niigata.
Yoshioka A; Ohkubo Y; Nishimura T; Tanaka I; Fukui H; Ogata K; Kamiya T; Takahashi H
Thromb Res; 1986 Jun; 42(5):595-604. PubMed ID: 3487139
[TBL] [Abstract][Full Text] [Related]
2. Factor IX Deventer-evidence for the heterogeneity of hemophilia BM.
Bertina RM; van der Linden IK
Thromb Haemost; 1982 Apr; 47(2):136-40. PubMed ID: 7101232
[TBL] [Abstract][Full Text] [Related]
3. A simple method for analyzing factor IX activation in the patients with hemophilia B variants.
Yoshioka A; Sakai T; Yamamoto K; Ohkubo Y; Fukui H
Thromb Haemost; 1987 Aug; 58(2):705-8. PubMed ID: 3499681
[TBL] [Abstract][Full Text] [Related]
4. Blood clotting factor IX Kashihara: amino acid substitution of valine-182 by phenylalanine.
Sakai T; Yoshioka A; Yamamoto K; Niinomi K; Fujimura Y; Fukui H; Miyata T; Iwanaga S
J Biochem; 1989 May; 105(5):756-9. PubMed ID: 2753873
[TBL] [Abstract][Full Text] [Related]
5. Characterization of the defect in activation of factor IX Chapel Hill by human factor XIa.
Braunstein KM; Noyes CM; Griffith MJ; Lundblad RL; Roberts HR
J Clin Invest; 1981 Dec; 68(6):1420-6. PubMed ID: 6976355
[TBL] [Abstract][Full Text] [Related]
6. Mutations in hemophilia Bm occur at the Arg180-Val activation site or in the catalytic domain of factor IX.
Bertina RM; van der Linden IK; Mannucci PM; Reinalda-Poot HH; Cupers R; Poort SR; Reitsma PH
J Biol Chem; 1990 Jul; 265(19):10876-83. PubMed ID: 2162822
[TBL] [Abstract][Full Text] [Related]
7. The Arg-4 mutant factor IX Strasbourg 2 shows a delayed activation by factor XIa.
de la Salle C; Charmantier JL; Ravanat C; Ohlmann P; Hartmann ML; Schuhler S; Bischoff R; Ebel C; Roecklin D; Balland A
Nouv Rev Fr Hematol (1978); 1993; 35(5):473-80. PubMed ID: 8295821
[TBL] [Abstract][Full Text] [Related]
8. Purification and properties of an abnormal blood coagulation factor IX (factor IXBm)/kinetics of its inhibition of factor X activation by factor VII and bovine tissue factor.
Osterud B; Kasper CK; Lavine KK; Prodanos C; Rapaport SI
Thromb Haemost; 1981 Feb; 45(1):55-9. PubMed ID: 7245126
[TBL] [Abstract][Full Text] [Related]
9. Blood clotting factor IX Niigata: substitution of alanine-390 by valine in the catalytic domain.
Sugimoto M; Miyata T; Kawabata S; Yoshioka A; Fukui H; Takahashi H; Iwanaga S
J Biochem; 1988 Dec; 104(6):878-80. PubMed ID: 3243764
[TBL] [Abstract][Full Text] [Related]
10. The abnormal factor IX of hemophilia B+ variants.
Bertina RM; Veltkamp JJ
Thromb Haemost; 1978 Oct; 40(2):335-49. PubMed ID: 734633
[TBL] [Abstract][Full Text] [Related]
11. Blood clotting factor IX Nagoya 3: the molecular defect of zymogen activation caused by an arginine-145 to histidine substitution.
Suehiro K; Miyata T; Takeya H; Takamatsu J; Saito H; Murakawa M; Okamura T; Niho Y; Iwanaga S
Thromb Res; 1990 Nov; 60(4):311-20. PubMed ID: 2087690
[TBL] [Abstract][Full Text] [Related]
12. Factor IX Zutphen. A genetic variant of blood coagulation factor IX with an abnormally high molecular weight.
Bertina RM; Van Der Linden IK
J Lab Clin Med; 1982 Nov; 100(5):695-704. PubMed ID: 7130828
[TBL] [Abstract][Full Text] [Related]
13. Factor IX variants of hemophilia B. The effect of activated factor XI and the reaction product of factor VII and tissue factor on the abnormal factor IX molecules.
Osterud B; Kasper CK; Prodanos C
Thromb Res; 1979; 15(1-2):235-43. PubMed ID: 483278
[No Abstract] [Full Text] [Related]
14. Molecular defect in factor IX Tokyo: substitution of valine-182 by alanine at position P2' in the second cleavage site by factor XIa resulting in impaired activation.
Maekawa H; Sugo T; Yamashita N; Kamiya K; Umeyama H; Miura N; Naka H; Nishimura T; Yoshioka A; Matsuda M
Biochemistry; 1993 Jun; 32(24):6146-51. PubMed ID: 8512923
[TBL] [Abstract][Full Text] [Related]
15. The mechanism of activation of bovine factor IX (Christmas factor) by bovine factor XIa (activated plasma thromboplastin antecedent).
Fujikawa K; Legaz ME; Kato H; Davie EW
Biochemistry; 1974 Oct; 13(22):4508-16. PubMed ID: 4473201
[No Abstract] [Full Text] [Related]
16. Blood clotting factor IX BM Nagoya. Substitution of arginine 180 by tryptophan and its activation by alpha-chymotrypsin and rat mast cell chymase.
Suehiro K; Kawabata S; Miyata T; Takeya H; Takamatsu J; Ogata K; Kamiya T; Saito H; Niho Y; Iwanaga S
J Biol Chem; 1989 Dec; 264(35):21257-65. PubMed ID: 2592373
[TBL] [Abstract][Full Text] [Related]
17. Characterization of three abnormal factor IX variants (Bm Lake Elsinore, Long Beach, and Los Angeles) of hemophilia-B. Evidence for defects affecting the latent catalytic site.
Usharani P; Warn-Cramer BJ; Kasper CK; Bajaj SP
J Clin Invest; 1985 Jan; 75(1):76-83. PubMed ID: 3965513
[TBL] [Abstract][Full Text] [Related]
18. Characterization of a factor IX variant with a glycine207 to glutamic acid mutation.
Lin SW; Lin CN; Hamaguchi N; Smith KJ; Shen MC
Blood; 1994 Sep; 84(6):1866-73. PubMed ID: 7915915
[TBL] [Abstract][Full Text] [Related]
19. Activation of factor IX by factor XIa--a spectrophotometric assay for factor IX in human plasma.
Tans G; Janssen-Claessen T; van Dieijen G; Hemker HC; Rosing J
Thromb Haemost; 1982 Oct; 48(2):127-32. PubMed ID: 6983739
[TBL] [Abstract][Full Text] [Related]
20. Large-scale production and properties of a solvent-detergent-treated factor IX concentrate from human plasma.
Michalski C; Bal F; Burnouf T; Goudemand M
Vox Sang; 1988; 55(4):202-10. PubMed ID: 3265237
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
